-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent years, as China's pharmaceutical reform has entered the deep water zone, and China's generic drug market has begun to transform to innovation
.
In this context, in order to maintain a competitive advantage in the Chinese market, multinational pharmaceutical companies have begun to closely follow China's pharmaceutical policies and make timely organizational structure and business model adjustments
.
In recent news, the multinational pharmaceutical company Astellas established its Greater China headquarters in Beijing and officially opened.
After this strategic layout upgrade, a new structure of one headquarters and two centers will be formed
.
Among them, Astellas Investment in Beijing, as its regional headquarters in Greater China, will be mainly responsible for overall planning, strategic decision-making, and resource coordination
.
Beijing Astellas Pharmaceuticals will serve as the company's marketing center for oncology and specialty treatment products in China, further focusing on manufacturing in China
.
The formation of this new structure will further promote the development of Astellas in the Chinese market
.
Statistics show that Astellas is a large multinational pharmaceutical company with operations in more than 70 countries and regions around the world
.
China regards it as a vital part of its global growth strategy
.
Astellas entered China in 1994 and brought innovative medicines and related services in various fields such as tumors, transplantation immunity, urinary, and infections
.
The Q1 report shows that Astellas’ performance in the Greater China region was 16.
4 billion yen (approximately US$150 million), a year-on-year increase of 15.
5%, surpassing other sales regions
.
After its product enzalutamide was included in the new medical insurance catalogue at the end of 2020 (implemented on March 1, 2021), its performance in the Greater China region was 1.
9 billion yen (approximately US$17 million), reaching a growth of 165.
1%
.
With the aging of the population and the advancement of the healthy China strategy, China's pharmaceutical and healthcare market has huge room for development, but at the same time the market is also undergoing rapid development and change, which requires major companies to continuously improve their operating efficiency to maintain industry competitiveness
.
It is reported that, in order to get closer to the needs of the Chinese market, Astellas established the Greater China region in April 2019, and carried out relevant reporting line upgrades and layout planning adjustments; and this strategic upgrade is the continuation and deepening of the company’s previous development strategy
.
In the future, the company will still focus its strategic focus on breakthroughs in oncology, innovative drugs and therapies
.
It is understood that since the beginning of this year, the company has continued to reap great results
.
For example, in February 2021, gerritinib (trade name: Segatan) was approved in China, mainly for the treatment of adult patients with relapsed or refractory acute myeloid leukemia carrying FLT3 mutations
.
The drug is another achievement of Astellas's commitment to developing innovative breakthrough solutions for refractory tumors with limited treatment options, and will bring good news to domestic patients
.
In addition, another targeted antibody drug in Astellas' new product pipeline, Zolbetuximab, aims to deal with the high incidence and high mortality of gastric cancer in China by targeting potential new targets
.
At present, the product has participated in global multi-center clinical trials in China and achieved global simultaneous development
.
In addition to focusing on innovative drugs for oncology, its product PADCEV was approved by the FDA in the United States in July 2021 for the treatment of locally advanced or metastatic urothelial cancer that is intolerant to cisplatin and has received one or more systemic treatments in the past.
Patient
.
It is reported that in order to benefit Chinese patients as soon as possible, the company has actively explored feasible solutions to accelerate the access of Chinese patients, and is expected to provide more Chinese patients with innovative and effective treatment options in the near future
.
.
In this context, in order to maintain a competitive advantage in the Chinese market, multinational pharmaceutical companies have begun to closely follow China's pharmaceutical policies and make timely organizational structure and business model adjustments
.
In recent news, the multinational pharmaceutical company Astellas established its Greater China headquarters in Beijing and officially opened.
After this strategic layout upgrade, a new structure of one headquarters and two centers will be formed
.
Among them, Astellas Investment in Beijing, as its regional headquarters in Greater China, will be mainly responsible for overall planning, strategic decision-making, and resource coordination
.
Beijing Astellas Pharmaceuticals will serve as the company's marketing center for oncology and specialty treatment products in China, further focusing on manufacturing in China
.
The formation of this new structure will further promote the development of Astellas in the Chinese market
.
Statistics show that Astellas is a large multinational pharmaceutical company with operations in more than 70 countries and regions around the world
.
China regards it as a vital part of its global growth strategy
.
Astellas entered China in 1994 and brought innovative medicines and related services in various fields such as tumors, transplantation immunity, urinary, and infections
.
The Q1 report shows that Astellas’ performance in the Greater China region was 16.
4 billion yen (approximately US$150 million), a year-on-year increase of 15.
5%, surpassing other sales regions
.
After its product enzalutamide was included in the new medical insurance catalogue at the end of 2020 (implemented on March 1, 2021), its performance in the Greater China region was 1.
9 billion yen (approximately US$17 million), reaching a growth of 165.
1%
.
With the aging of the population and the advancement of the healthy China strategy, China's pharmaceutical and healthcare market has huge room for development, but at the same time the market is also undergoing rapid development and change, which requires major companies to continuously improve their operating efficiency to maintain industry competitiveness
.
It is reported that, in order to get closer to the needs of the Chinese market, Astellas established the Greater China region in April 2019, and carried out relevant reporting line upgrades and layout planning adjustments; and this strategic upgrade is the continuation and deepening of the company’s previous development strategy
.
In the future, the company will still focus its strategic focus on breakthroughs in oncology, innovative drugs and therapies
.
It is understood that since the beginning of this year, the company has continued to reap great results
.
For example, in February 2021, gerritinib (trade name: Segatan) was approved in China, mainly for the treatment of adult patients with relapsed or refractory acute myeloid leukemia carrying FLT3 mutations
.
The drug is another achievement of Astellas's commitment to developing innovative breakthrough solutions for refractory tumors with limited treatment options, and will bring good news to domestic patients
.
In addition, another targeted antibody drug in Astellas' new product pipeline, Zolbetuximab, aims to deal with the high incidence and high mortality of gastric cancer in China by targeting potential new targets
.
At present, the product has participated in global multi-center clinical trials in China and achieved global simultaneous development
.
In addition to focusing on innovative drugs for oncology, its product PADCEV was approved by the FDA in the United States in July 2021 for the treatment of locally advanced or metastatic urothelial cancer that is intolerant to cisplatin and has received one or more systemic treatments in the past.
Patient
.
It is reported that in order to benefit Chinese patients as soon as possible, the company has actively explored feasible solutions to accelerate the access of Chinese patients, and is expected to provide more Chinese patients with innovative and effective treatment options in the near future
.
